Amitriptyline Mefloquine Combination for CNS Hemichannel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tricyclic antidepressants like amitriptyline have limited efficacy and are associated with poorly tolerated side effects, and existing combinations with HC-blocking agents do not effectively enhance therapeutic effects while reducing side effects for conditions such as neuropathic pain and neurodegenerative disorders.
Innovation Solution
A combination product of amitriptyline and a low dose of mefloquine is proposed, where amitriptyline is found to inhibit CNS hemichannels, particularly Cx43, and the synergy between amitriptyline and mefloquine enhances therapeutic effects in animal models of neuropathic pain, depression, and neuro-inflammation without increasing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amitriptyline is used at higher doses to improve therapeutic efficacy, then therapeutic effect is enhanced, but side effects increase
Solution Approach 1:
The patent combines amitriptyline with mefloquine in a fixed-ratio formulation (e.g., 10:1 or 5:1 weight ratio) to achieve synergistic therapeutic effects. This combination allows lower doses of amitriptyline to be used while maintaining or enhancing efficacy, thereby reducing side effects associated with high-dose monotherapy.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both amitriptyline and mefloquine. This composite approach leverages the complementary mechanisms of action of the two compounds, where mefloquine blocks hemichannels and amitriptyline provides antidepressant and analgesic effects, resulting in enhanced therapeutic profile with reduced adverse effects.
2Object-affected harmful factors
If treatment is initiated with low doses of amitriptyline to reduce side effects, then side effects are minimized, but beneficial effects are delayed
Solution Approach 1:
By combining amitriptyline with mefloquine from the start of treatment, the formulation provides immediate synergistic action. Mefloquine's rapid hemichannel blocking effect complements amitriptyline's slower-acting mechanisms, enabling therapeutic benefits to be achieved more quickly without requiring gradual dose escalation.
3Reliability
If amitriptyline is combined with HC-blocking agents to enhance therapeutic effect, then efficacy is improved, but side effects are not reduced
Solution Approach 1:
The patent specifically optimizes the dose ratio between amitriptyline and mefloquine (e.g., 10:1 or 5:1), using a low dose of mefloquine combined with a standard or reduced dose of amitriptyline. This parameter optimization achieves synergistic efficacy while minimizing side effects, distinguishing it from previous combinations that used equimolar or non-optimized ratios.
Data Source
Figure 1
Figure 2A~2D
Figure 3~4
AI summary
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (notably neuropathic pain, neurodegenerative disorders, ischemic brain injury and inflammatory intestinal conditions). Additionally, the invention provides a method to enhance the therapeutic effect of amitriptyline for its common indications. The method of the invention involves combining amitriptyline with another HC-blocking agent, mefloquine.